Titlebook: Neuropsychopharmacology; W. Wolfgang Fleischhacker,David J. Brooks Conference proceedings 2003 Springer-Verlag Wien 2003 Parkinson‘s disea

Strategy

書目名稱Neuropsychopharmacology影響因子(影響力)




書目名稱Neuropsychopharmacology影響因子(影響力)學(xué)科排名




書目名稱Neuropsychopharmacology網(wǎng)絡(luò)公開度




書目名稱Neuropsychopharmacology網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Neuropsychopharmacology被引頻次




書目名稱Neuropsychopharmacology被引頻次學(xué)科排名




書目名稱Neuropsychopharmacology年度引用




書目名稱Neuropsychopharmacology年度引用學(xué)科排名




書目名稱Neuropsychopharmacology讀者反饋




書目名稱Neuropsychopharmacology讀者反饋學(xué)科排名

陪審團(tuán)每個(gè)人

Advances in the Pharmacological Management of Parkinson Disease,on. Finally preliminary reports suggest that Cholinesterase inhibitors, such as rivastigmine, can be usefull in the management of cognitive impairment in PD, one of the most difficult clinical problems encountered in the management of this neurodegenerative disorder.

把…比做

Autobiography

Therapeutic implications of constitutive activity of receptors: the example of the histamine H3 recntrinsic activity, we show that the native H. receptor in brain displays high constitutive activity in vitro and, in vivo, controls the release of endogenous histamine. This implies that inverse agonists with high intrinsic activity should be preferred for therapeutic application as “cognitive enhancers” in several psychiatric disorders.

痛得哭了

BOOR

https://doi.org/10.1007/978-3-7091-6020-6Parkinson‘s disease; migraine; movement disorders; psychiatric disorders; schizophrenia; serotonin disord

證明無罪

978-3-211-83902-7Springer-Verlag Wien 2003

Agility

Neuropsychopharmacology978-3-7091-6020-6Series ISSN 0303-6995

防銹

0303-6995 Overview: 978-3-211-83902-7978-3-7091-6020-6Series ISSN 0303-6995

FORGO